FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System
This article was originally published in The Gray Sheet
Executive Summary
A recent FDA inspection of Medtronic’s diabetes business identified quality systems deficiencies that are likely to delay the firm’s launch of its first-of-a-kind MiniMed 530G insulin pump/continuous glucose monitoring system.